IR@PKUHSC  > 北京大学临床肿瘤学院  > 胃肠肿瘤中心
学科主题临床医学
Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer
Li, Fang-Hua1,2; Shen, Lin3; Li, Zhuang-Hua1; Luo, Hui-Yan1; Qiu, Miao-Zhen1; Zhang, Hui-Zhong4; Li, Yu-Hong1; Xu, Rui-Hua1
关键词Cetuximab Metastatic colorectal cancer KRAS mutation Phosphatase and tensin protein expression
刊名WORLD JOURNAL OF GASTROENTEROLOGY
2010-12-14
DOI10.3748/wjg.v16.i46.5881
16期:46页:5881-5888
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]GROWTH-FACTOR RECEPTOR ; TYROSINE KINASE INHIBITORS ; CELL LUNG-CANCER ; K-RAS MUTATIONS ; PLUS IRINOTECAN ; PHASE-II ; CHEMOTHERAPY ; OXALIPLATIN ; RESISTANCE ; EFFICACY
英文摘要

AIM: To investigate the prognostic value of KRAS mutation, and phosphatase and tensin (PTEN) expression in Chinese metastatic colorectal cancer metastatic colorectal cancer (mCRC) patients treated with cetuximab.

METHODS: Ninety Chinese mCRC patients treated with cetuximab were evaluated for KRAS mutation and PTEN protein expression by DNA sequencing of codons 12 and 13 and immunohistochemistry, respectively. We then selected 61 patients treated with cetuximab, either in combination with chemotherapy, or alone as a second-line or third-line regimen to assess whether KRAS mutation or PTEN protein expression is associated with the response and the survival time of mCRC patients treated with cetuximab.

RESULTS: KRAS mutation was found in 30 (33.3%) tumor samples from the 90 patients, and positive PTEN expression was detected in 58 (64.4%) of the 90 patients. Among the 61 patients who were treated with cetuximab as a second-line or third-line regimen, the resistance to cetuximab was found in 22 patients with KRAS mutation and in 39 patients without KRAS mutation, with a response rate of 4.5% and 46.1% respectively (P = 0.001), a shorter median progression-free survival (PFS) time of 14 +/- 1.3 wk and 32 +/- 2.5 wk respectively (P < 0.001), a median overall survival (OS) time of 11 +/- 1.2 mo and 19 +/- 1.8 mo respectively (P < 0.001), as well as in 24 patients with negative PTEN expression and in 37 patients with positive PTEN expression respectively (P < 0.001), with a responsive rate of 4.2% and 48.6% respectively, a shorter median PFS survival time of 17 +/- 2.0 wk and 28 +/- 1.9 wk respectively (P = 0.07), and a median OS time of 11 +/- 1.3 mo and 18 +/- 1.9 mo respectively (P = 0.004). Combined KRAS mutation and PTEN expression analysis showed that the PFS and OS time of patients with two favorable prognostic factors were longer than those of patients with one favorable prognostic factor or no favorable prognostic factor (P < 0.001).

CONCLUSION: KRAS mutation and PTEN protein expression are significantly correlated with the response rate and survival time of Chinese mCRC patients treated with cetuximab. (C) 2010 Baishideng. All rights reserved.

语种英语
WOS记录号WOS:000285448500014
资助机构Program for New Century Excellent Talents in University
引用统计
被引频次:16[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58230
专题北京大学临床肿瘤学院_胃肠肿瘤中心
北京大学临床肿瘤学院_消化肿瘤内科
作者单位1.Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, State Key Lab Oncol So China, Guangzhou 510060, Guangdong, Peoples R China
2.Shengli Oil Field Cent Hosp, Dept Med Oncol, Dongying 257034, Shandong, Peoples R China
3.Peking Univ, Sch Oncol, Dept GI Oncol, Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China
4.Sun Yat Sen Univ, Ctr Canc, Dept Pathol, State Key Lab Oncol So China, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
Li, Fang-Hua,Shen, Lin,Li, Zhuang-Hua,et al. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2010,16(46):5881-5888.
APA Li, Fang-Hua.,Shen, Lin.,Li, Zhuang-Hua.,Luo, Hui-Yan.,Qiu, Miao-Zhen.,...&Xu, Rui-Hua.(2010).Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer.WORLD JOURNAL OF GASTROENTEROLOGY,16(46),5881-5888.
MLA Li, Fang-Hua,et al."Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer".WORLD JOURNAL OF GASTROENTEROLOGY 16.46(2010):5881-5888.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Fang-Hua]的文章
[Shen, Lin]的文章
[Li, Zhuang-Hua]的文章
百度学术
百度学术中相似的文章
[Li, Fang-Hua]的文章
[Shen, Lin]的文章
[Li, Zhuang-Hua]的文章
必应学术
必应学术中相似的文章
[Li, Fang-Hua]的文章
[Shen, Lin]的文章
[Li, Zhuang-Hua]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。